A method for providing a passivation layer or pH protective coating on a substrate surface by PECVD is provided, the method comprising generating a plasma from a gaseous reactant comprising polymerizing gases. The lubricity, passivation, pH protective, hydrophobicity, and/or barrier properties of the passivation layer or pH protective coating are set by setting the ratio of the O.sub.2 to the organosilicon precursor in the precursor feed, and/or by setting the electric power used for generating the plasma. In particular, a passivation layer or pH protective coating made by the method is provided. Pharmaceutical packages coated by the method and the use of such packages protecting composition contained in the vessel against mechanical and/or chemical effects of the surface of the package without a passivation layer or pH protective coating material are also provided.

The present invention relates to a prefilled glass container, such as a prefilled glass syringe, comprising an aqueous botulinum toxin formulation. The aqueous botulinum toxin formulation in the prefilled container is stable at low to ambient temperature for a prolonged time period. Furthermore, the present invention relates to a kit comprising the botulinum toxin prefilled container, and to the use of the botulinum toxin prefilled container in therapeutic and cosmetic applications.

The invention relates to a lubricant coating (5) for a medical injection device (1), comprising successively: —a bottom layer (50) in contact with the medical device surface (21) of the container to be lubricated, comprising a mixture of cross-linked and non-cross-linked poly-(dimethylsiloxane), —an intermediate layer (51) consisting essentially of oxidized poly-(dimethylsiloxane) and having a thickness comprised between 10 and 30 nm and, —a top layer (52) consisting essentially of non-cross-linked poly-(dimethylsiloxane) and having a thickness of at most 2 nm. The invention also relates to a medical injection device comprising such a lubricant coating, and a manufacturing process for said coating.

A package including a vessel wherein at least a portion of the vessel wall is made of a double wall material is disclosed. The double wall material comprises an interior polymer layer enclosed by an exterior polymer layer and one of the polymer layers is a layer made of cyclic olefin polymer (COP) resin. The package comprising the double wall, a CVD coating set on the wall, and a medicament comprising at least one protein, peptide, and/or DNA sequence is disclosed. Methods for processing a vessel, for example to provide lubricity or hydrophobicity, are also disclosed. The interior surface of the seated vessel can be processed via the vessel port by PECVD. Vessel barrier, lubricity and hydrophobic coatings and coated vessels, for example syringes and medical sample collection tubes are disclosed.

A container having a barrier layer is provided. The container may be of thermoplastic and the barrier may inhibit materials from leaching from the thermoplastic material or from extraction of compounds from medicants by the thermoplastic. A process is also described that allows for molding thin barrier layers as container lines and for forming thermoplastic containers with barrier liners.

One embodiment is directed to a system for injecting, comprising a syringe body defining an interior medicine chamber; a stopper member configured to be inserted into the interior medicine chamber to contain medicine within the medicine chamber; a plunger member configured to be manually manipulated to insert the stopper member relative to the syringe body; and a needle having proximal and distal ends, the proximal end comprising an anchoring geometry configured to be at least partially inserted into the stopper member such that upon retraction of the stopper member, the needle is pulled proximally along with the stopper to be at least partially contained within the interior medicine chamber.

A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.

A high-slidability syringe has high safety and sealability over a long period of time. The syringe includes a gasket having a lower sliding resistance to a syringe barrel. The syringe includes: a syringe barrel; a gasket adapted to be press-fitted in the syringe barrel and used in a sliding manner in the syringe barrel; and a piston rod with the gasket attached to a front end thereof. The gasket includes: a gasket main body that is formed of a rigid plastic having resistance to a drug solution to be loaded into the syringe barrel and has a recessed groove formed in a sliding contact surface thereof adapted to slidably contact an inner circumferential surface of the syringe barrel; and a sliding contact ring that is fitted in the recessed groove.

A syringe cap is configured to be removably attached to a barrel to seal a needle hole in a puncture needle held by a barrel tip portion of the barrel, and comprises a first member that is configured to be pierced with the puncture needle and that comprises an elastic material having a Young's modulus in the range of 1 to 10 MPa; and a second member that comprises an elastic hollow body having a Young's modulus in the range of 1 to 10 MPa and that is configured form a closed space between the first member and the barrel. A vapor permeability of a material from which the first member is formed is lower than a vapor permeability of a material from which the second member is formed.

A drug container includes a container body formed of a thermoplastic resin containing a cyclic polyolefin as a main component. The thermoplastic resin contains, as a lubricant, at least one compound selected from among a metal soap compound, an organic fatty acid ester compound, a synthetic wax compound, and a fatty acid amide compound. The lubricant content of the thermoplastic resin is 0.3 to 2.0 μg/g.